We are live on ! Find out more
BNTC icon

Benitec Biopharma
BNTC

4 hedge funds and large institutions have $337K invested in Benitec Biopharma in 2020 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more capital invested

Capital invested by funds: $198K → $337K (+$139K)

0.23% more ownership

Funds ownership: 0% → 0.23% (+0.23%)

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$81.2K
2
UBS Group
UBS Group
Switzerland
+$10.4K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$20.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$232K +$81.2K +601 +53%
SM
2
Sabby Management
Florida
$94K -$20.1K -149 -18%
UBS Group
3
UBS Group
Switzerland
$10K +$10.4K +77 New
JP Morgan Chase
4
JP Morgan Chase
New York
$1K – – –
RE
5
RBC Europe
United Kingdom
$47 – – –

BNTC Hedge Fund Activity: Q2 2020 in Review

4 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q2 2020, worth a combined $337K — up 70% from $198K a quarter earlier.

Fund positioning in BNTC was balanced in Q2 2020: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $81.2K. The largest seller was Sabby Management, cutting an estimated $20.1K.

  • 4 institutional investors held Benitec Biopharma (BNTC) as of Q2 2020, unchanged from Q1 2020.
  • Funds reported $337K of Benitec Biopharma stock for Q2 2020, up 70% quarter-over-quarter.
  • 1 fund opened new Benitec Biopharma positions in Q2 2020 and 1 closed out, a net change of 0 holders.
  • The largest Benitec Biopharma buyer in Q2 2020 was Morgan Stanley, an estimated $81.2K added.
  • The largest Benitec Biopharma seller in Q2 2020 was Sabby Management, an estimated $20.1K sold.

Based on aggregated 13F filings for Q2 2020.